Legal & General Group Plc Takes Position in Ralliant Corporation $RAL

Key Points

• Legal & General Group Plc acquired 249,207 Ralliant shares worth approximately $18.3 million, giving it a 0.23% stake. Several other institutional investors also initiated or increased positions during the second quarter.
• Analyst sentiment remains broadly positive, with Ralliant carrying a “Moderate Buy” consensus rating and an average price target of $75.70, despite some rating reductions to “Hold.”
• Ralliant reported quarterly EPS of $0.68, beating estimates of $0.63, and issued fiscal 2026 EPS guidance of $2.76–$2.90. The company also announced a $0.05 quarterly dividend, while its CEO and a senior vice president disclosed shares sold under pre-arranged trading plans.

Legal & General Group Plc acquired a new stake in Ralliant Corporation (NYSE:RAL - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 249,207 shares of the company's stock, valued at approximately $18,349,000. Legal & General Group Plc owned about 0.23% of Ralliant as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in RAL. The Manufacturers Life Insurance Company acquired a new position in Ralliant during the 2nd quarter valued at about $7,351,000. Group One Trading LLC bought a new position in Ralliant in the second quarter valued at approximately $36,000. Algert Global LLC lifted its stake in shares of Ralliant by 439.9% in the 2nd quarter. Algert Global LLC now owns 126,010 shares of the company's stock valued at $9,278,000 after purchasing an additional 102,670 shares during the period. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Ralliant in the 2nd quarter valued at $8,493,000. Finally, Globeflex Capital L P bought a new position in shares of Ralliant in the 2nd quarter worth $623,000.

Analyst Upgrades and Downgrades

RAL has been the topic of a number of recent analyst reports. Zacks Research upgraded Ralliant from a "hold" rating to a "strong-buy" rating in a report on Tuesday, June 30th. Vertical Research cut shares of Ralliant from a "buy" rating to a "hold" rating and set a $65.00 price objective for the company. in a report on Wednesday, May 27th. Morgan Stanley lifted their price target on shares of Ralliant from $68.00 to $85.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 23rd. Truist Financial reissued a "buy" rating and issued a $82.00 price target (up from $68.00) on shares of Ralliant in a report on Friday, July 31st. Finally, BMO Capital Markets started coverage on Ralliant in a report on Monday, July 20th. They set a "market perform" rating and a $78.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $75.70.

Insider Buying and Selling at Ralliant

In related news, SVP Karen M. Bick sold 6,062 shares of Ralliant stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the sale, the senior vice president owned 31,668 shares of the company's stock, valued at approximately $2,280,096. The trade was a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the company's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the sale, the chief executive officer owned 251,967 shares in the company, valued at $18,088,710.93. The trade was a 4.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by insiders.

Ralliant Trading Down 0.1%

NYSE RAL opened at $61.65 on Monday. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of -5.68, a PEG ratio of 2.29 and a beta of 1.61. The stock's 50 day moving average price is $68.40 and its two-hundred day moving average price is $56.53. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $75.41.

Ralliant (NYSE:RAL - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.05. The firm had revenue of $567.80 million during the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, analysts anticipate that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be given a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant's dividend payout ratio (DPR) is -1.84%.

Ralliant Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source